Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan
Open accessThe DOI matches its Crossref record; 86 of the 89 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Polycystic ovary syndrome (PCOS) is of clinical and public health importance as it is very common, affecting up to one in five women of reproductive age. It has significant and diverse clinical implications including reproductive (infertility, hyperandrogenism, hirsutism), metabolic (insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, adverse cardiovascular risk profiles) and psychological features (increased anxiety, depression and worsened quality of life). Polycystic ovary syndrome is a heterogeneous condition and, as such, clinical and research agendas are broad and involve many disciplines. The phenotype varies widely depending on life stage, genotype, ethnicity and environmental factors including lifestyle and bodyweight. Importantly, PCOS has unique interactions with the ever increasing obesity prevalence worldwide as obesity-induced insulin resistance significantly exacerbates all the features of PCOS. Furthermore, it has clinical implications across the lifespan and is relevant to related family members with an increased risk for metabolic conditions reported in first-degree relatives. Therapy should focus on both the short and long-term reproductive, metabolic and psychological features. Given the aetiological role of insulin resistance and the impact of obesity on both hyperinsulinaemia and hyperandrogenism, multidisciplinary lifestyle improvement aimed at normalising insulin resistance, improving androgen status and aiding weight management is recognised as a crucial initial treatment strategy. Modest weight loss of 5% to 10% of initial body weight has been demonstrated to improve many of the features of PCOS. Management should focus on support, education, addressing psychological factors and strongly emphasising healthy lifestyle with targeted medical therapy as required. Monitoring and management of long-term metabolic complications is also an important part of routine clinical care. Comprehensive evidence-based guidelines are needed to aid early diagnosis, appropriate investigation, regular screening and treatment of this common condition. Whilst reproductive features of PCOS are well recognised and are covered here, this review focuses primarily on the less appreciated cardiometabolic and psychological features of PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schema of aetiology and clinical features including reproductive, metabolic and psychosocial features of polycystic ovary syndrome (PCOS). Reproduced with permission from [82].](https://figures.cochat.ai/paper-figures/ba6dd207954c4ccea0560e719bee27b2/polycystic-ovary-syndrome-a-complex-condition-with-psychological-reproductive-figure-1.jpg)
![Figure 2 Summary of a targeted approach to therapy in polycystic ovary syndrome (PCOS). Reproduced with permission from [82].](https://figures.cochat.ai/paper-figures/aea8c8d83d0748a1af73bd3d99542ce7/polycystic-ovary-syndrome-a-complex-condition-with-psychological-reproductive-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PCOS prevalence is between 10% and 13% as confirmed in the guideline process. 1,2”
From Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PCOS prevalence is between 10% to 13% as confirmed in the guideline process (1, 2).”
From Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting reproductive-aged women, with impacts across the lifespan from adolescence to post menopause.”
From Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“PCOS aetiology is complex”
From Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“clinical presentation is heterogeneous with reproductive, metabolic, and psychological features (1, 2).”
From Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023) · cites this paper as [1]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427 · cited 4×
“Some studies support an increased risk of CVD in PCOS [18], but these findings are not universal [61] and further research is needed.”
InfluentialRetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 4×
“• Metformin* reduces the risk of diabetes by approximately 50% in high-risk groups [49].”
Influential(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712 · cited 2×
“Proc Natl Acad Sci USA 2006, 103:7030-7035.”
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458 · cited 2×
“Interestingly, there is a paradoxical expression of insulin resistance in PCOS whereby insulin-stimulated androgen production persists while its role in glucose metabolism is impaired [42].”
Men at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 8×
“National Institutes of Health criteria consensus statement [83] European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine consensus statement [20] Androgen Excess Society position statement [ 21 ]”
InfluentialAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132 · cited 1×
“Among those with amenorrhoea, only 40% will be diagnosed with PCOS as hypothalamic dysfunction is a more common cause [ 31 ].”
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 2×
“Lean women with PCOS often but not always [13] have abnormalities of insulin secretion and action compared to weight-matched control subjects [41].”
March, W. A., Moore, V. M., Willson, K. J., Phillips, D. I. W., Norman, R. J., & Davies, M. J. (2010) · Human Reproduction · doi:10.1093/humrep/dep399 · Cited by 1,799 · cited 4×
“8%) in the first community-based prevalence study based on current Rotterdam diagnostic criteria [5].”
InfluentialLegro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743 · cited 5×
“However, impaired fasting glucose is a poor predictor of IGT in women in general [50] and in PCOS [27,43].”
InfluentialDansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P., & Schaefer, E. J. (2005) · JAMA · doi:10.1001/jama.293.1.43 · Cited by 1,726 · cited 1×
“Standard dietary management of obesity and related comorbidities [70] is a nutritionally adequate, low fat (approximately 30% of energy, saturated fat approximately 10%), moderate protein (approximately 15%) and high carbohydrate intake (approximately 55%), with increased fibre-rich wholegrain breads, cereals, fruits…”
Knochenhauer, E. S., Key, T. J., Kahsar-Miller, M., Waggoner, W., Boots, L. R., & Azziz, R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5090 · Cited by 1,516
Norman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61345-2 · Cited by 1,360
Asunción, M., Calvo, R. M., San Millán, J. L., Sancho, J., Avila, S., & Escobar-Morreale, H. F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6682 · Cited by 1,318
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 2×
“Women with PCOS also develop abnormal glucose metabolism at a younger age and may demonstrate a more rapid conversion from IGT to DM2 [43].”
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/er.18.6.774 · Cited by 1,155
Androgen Excess in Women: Experience with Over 1000 Consecutive Patients
Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J., Stephens, K. C., Taylor, K., & Boots, L. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031122 · Cited by 1,132 · cited 1×
“PCOS has also been noted to affect 28% of unselected obese and 5% of lean women [5-8].”
Knochenhauer, E. S. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.9.3078 · Cited by 1,127
Diamanti‐Kandarakis, E., Kouli, C., Bergiele, A. T., Filandra, F. A., Tsianateli, T. C., Spina, G., Zapanti, E. D., & Bartzis, M. I. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.11.4006 · Cited by 1,110 · cited 2×
“Proc Natl Acad Sci USA 2006, 103:7030-7035.”
Andrology: Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients
Balen, A. H., Conway, G. S., Kaltsas, G., Techatraisak, K., Manning, P. J., West, C., & Jacobs, H. S. (1995) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a136243 · Cited by 1,060 · cited 2×
“Obesity increases hyperandrogenism, hirsutism, infertility and pregnancy complications both independently and by exacerbating PCOS [16,17].”
(2016) · Dietetic and Nutrition Case Studies · doi:10.1002/9781119163411.ch73 · Cited by 1,013
Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1045 · Cited by 931
A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome
Boomsma, C. M., Eijkemans, M. J. C., Hughes, E. G., Visser, G. H. A., Fauser, B. C. J. M., & Macklon, N. S. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml036 · Cited by 852 · cited 1×
“Women with PCOS may therefore present with a variety of serious clinical sequalae including psychological problems (reduced quality of life, poor self-esteem, depression, anxiety) [23,24], reproductive manifestations (hirsutism, infertility and pregnancy complications) [25], and metabolic implications (insulin resista…”
Asuncion, M. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.7.2434 · Cited by 791
Clark, A. M., Thornley, B., Tomlinson, L., Galletley, C., & Norman, R. J. (1998) · Human Reproduction · doi:10.1093/humrep/13.6.1502 · Cited by 789 · cited 4×
“With regards to fertility, the estimated cost per birth in overweight Australian women with PCOS is high [9].”
InfluentialInternational Diabetes Federation: a consensus on Type 2 diabetes prevention
Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02157.x · Cited by 778 · cited 2×
“Based on International Diabetes Federation recommendations [48,80], metformin has a role in prevention of diabetes where lifestyle therapy is inadequate.”
Barr, E. L. M., Zimmet, P. Z., Welborn, T. A., Jolley, D., Magliano, D. J., Dunstan, D. W., Cameron, A. J., Dwyer, T., Taylor, H. R., Tonkin, A. M., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685628 · Cited by 719 · cited 1×
“Given that large longitudinal cohort studies have reported up to 65% of CVD deaths occur in subjects with impaired glucose metabolism [60] and that IGT and DM2 are increased in PCOS, it would be expected that women with PCOS would have increased CVD risk.”
Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Ehrmann, D. A., Liljenquist, D. R., Kasza, K., Azziz, R., Legro, R. S., & Ghazzi, M. N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1329 · Cited by 703 · cited 1×
“Also, increased early clinical and subclinical markers of atherosclerosis seen in PCOS (endothelial dysfunction, impaired pulse wave velocity, increased carotid intima media wall thickness, presence of carotid plaque and increased coronary artery calcification) [34,57] are further exacerbated by obesity [27,58, 59 ].”
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome
Legro, R. S., Kunselman, A. R., & Dunaif, A. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00948-2 · Cited by 622 · cited 1×
“Also, increased early clinical and subclinical markers of atherosclerosis seen in PCOS (endothelial dysfunction, impaired pulse wave velocity, increased carotid intima media wall thickness, presence of carotid plaque and increased coronary artery calcification) [34,57] are further exacerbated by obesity [27,58,59].”
Azziz, R., Marin, C., Hoq, L., Badamgarav, E., & Song, P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0628 · Cited by 537 · cited 2×
“PCOS has also been noted to affect 28% of unselected obese and 5% of lean women [5-8].”
Moran, L. J., Noakes, M., Clifton, P. M., Tomlinson, L., & Norman, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020815 · Cited by 530 · cited 1×
“A number of small studies assessing specific dietary approaches in PCOS show similar results for diets moderately increased in dietary protein or carbohydrate [73-75] with one study reporting greater weight loss where a high protein supplement was added to a standard energy reduced diet [76].”
Self-citationProfound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
Dunaif, A. E., Segal, K. R., Futterweit, W., et al. (1989) · Diabetes · doi:10.2337/diabetes.38.9.1165 · Cited by 518
Mortality of Women with Polycystic Ovary Syndrome at Long-term Follow-up
Pierpoint, T., McKeigue, P. M., Isaacs, A. J., Wild, S. H., & Jacobs, H. S. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00035-3 · Cited by 504 · cited 1×
“Some studies support an increased risk of CVD in PCOS [18], but these findings are not universal [61] and further research is needed.”
Lipoprotein Lipid Concentrations and Cardiovascular Risk in Women with Polycystic Ovary Syndrome
WILD, R. A., PAINTER, P. C., COULSON, P. B., CARRUTH, K. B., & RANNEY, G. B. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-61-5-946 · Cited by 482 · cited 4×
“Metabolic features of PCOS Dyslipidaemia Dyslipidaemia is common in PCOS compared to weight matched controls [ 34-37 ], with higher triglycerides and lower high density lipoprotein cholesterol [35].”
InfluentialDetecting Insulin Resistance in Polycystic Ovary Syndrome: Purposes and Pitfalls
Legro, R. S., Castracane, V. D., & Kauffman, R. P. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000109523.25076.e2 · Cited by 453 · cited 2×
“Insulin resistance occurs in around 50% to 80% of women with PCOS [12], primarily in the more severe NIH diagnosed PCOS and in those who are overweight.”
Dunaif, A. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.3.942 · Cited by 450 · cited 1×
“Specific abnormalities of insulin metabolism identified in PCOS include reductions in secretion [39,40], reduced hepatic extraction [40], impaired suppression of hepatic gluconeogenesis [41] and abnormalities in insulin receptor signalling [42].”
Coviello, A. D., Legro, R. S., & Dunaif, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1666 · Cited by 447 · cited 1×
“However, when combined with obesity, metabolic implications of PCOS such as IGT, DM2 and the metabolic syndrome can present in adolescence [28,29].”
Moran, L. J., Pasquali, R., Teede, H. J., Hoeger, K. M., & Norman, R. J. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.09.018 · Cited by 444 · cited 4×
“Treatment of obesity through lifestyle intervention is a key treatment strategy in PCOS and improves insulin resistance, reproductive and metabolic features [19].”
InfluentialSelf-citationKIDDY, D. S., SHARP, P. S., WHITE, D. M., SCANLON, M. F., MASON, H. D., BRAY, C. S., POLSON, D. W., REED, M. J., & FRANKS, S. (1990) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1990.tb00857.x · Cited by 364 · cited 2×
“Obesity increases hyperandrogenism, hirsutism, infertility and pregnancy complications both independently and by exacerbating PCOS [16,17].”
Metabolic features of the reproductive phenotypes of polycystic ovary syndrome
Moran, L., & Teede, H. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp008 · Cited by 362 · cited 5×
“Conversely, lean women [13] and women with milder PCOS diagnosed on newer European Society for Human Reproduction (ESHRE)/ American Society of Reproductive Medicine (ASRM) criteria [14] appear to have less severe hyperinsulinaemia and insulin resistance.”
InfluentialSelf-citationScreening for Abnormal Glucose Tolerance in Adolescents with Polycystic Ovary Syndrome
Palmert, M. R., Gordon, C. M., Kartashov, A. I., Legro, R. S., Emans, S. J., & Dunaif, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8305 · Cited by 354 · cited 1×
“However, when combined with obesity, metabolic implications of PCOS such as IGT, DM2 and the metabolic syndrome can present in adolescence [28,29].”
Prevalence and Characteristics of the Polycystic Ovary Syndrome in Overweight and Obese Women
Álvarez-Blasco, F., Botella-Carretero, J. I., San Millán, J. L., & Escobar-Morreale, H. F. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2081 · Cited by 348
Norman, R. J., Masters, L., Milner, C. R., Wang, J. X., & Davies, M. J. (2001) · Human Reproduction · doi:10.1093/humrep/16.9.1995 · Cited by 341 · cited 1×
“2 years) in women with PCOS [45], however this has not been uniformly reported [46].”
Salley, K. E. S., Wickham, E. P., Cheang, K. I., Essah, P. A., Karjane, N. W., & Nestler, J. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1549 · Cited by 336
Talbott, E., Clerici, A., Berga, S. L., Kuller, L., Guzick, D., Detre, K., Daniels, T., & Engberg, R. A. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00010-9 · Cited by 315 · cited 1×
“Dyslipidaemia is common in PCOS compared to weight matched controls [34-37], with higher triglycerides and lower high density lipoprotein cholesterol [35].”
Changes in Glucose Tolerance over Time in Women with Polycystic Ovary Syndrome: A Controlled Study
Legro, R. S., Gnatuk, C. L., Kunselman, A. R., & Dunaif, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1843 · Cited by 306 · cited 1×
“2 years) in women with PCOS [45], however this has not been uniformly reported [46].”
Molecular mechanisms of insulin resistance in polycystic ovary syndrome
Diamanti-Kandarakis, E., & Papavassiliou, A. G. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.05.006 · Cited by 301 · cited 2×
“The cause of insulin resistance is likewise complex and multifactorial with genetic and environmental contributors [15].”
Overweight Women with Polycystic Ovary Syndrome Have Evidence of Subclinical Cardiovascular Disease
Meyer, C., McGrath, B. P., & Teede, H. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0011 · Cited by 273 · cited 2×
“Also, increased early clinical and subclinical markers of atherosclerosis seen in PCOS (endothelial dysfunction, impaired pulse wave velocity, increased carotid intima media wall thickness, presence of carotid plaque and increased coronary artery calcification) [34,57] are further exacerbated by obesity [27,58,59].”
Self-citationHuber-Buchholz, M.-M. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1470 · Cited by 269 · cited 1×
“fertility) [9,67] and metabolic features (insulin resistance and risk factors for CVD and DM2).”
(2022) · Cambridge University Press eBooks · doi:10.1017/9781108989831 · Cited by 254
Stamets, K., Taylor, D. S., Kunselman, A., Demers, L. M., Pelkman, C. L., & Legro, R. S. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.08.023 · Cited by 252 · cited 1×
“A number of small studies assessing specific dietary approaches in PCOS show similar results for diets moderately increased in dietary protein or carbohydrate [73-75] with one study reporting greater weight loss where a high protein supplement was added to a standard energy reduced diet [76].”
Optimal Gestational Weight Gain for Body Mass Index Categories
Cedergren, M. I. (2007) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000279450.85198.b2 · Cited by 249 · cited 1×
“There is currently an active debate about the appropriate limit for body mass index for assisted reproduction therapies, given the reduced success rates and the demonstrated risks of pregnancy in overweight women [32].”
Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation
Deeks, A. A., Gibson-Helm, M. E., & Teede, H. J. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.09.018 · Cited by 246 · cited 2×
“The challenges to feminine identity and body image due to obesity, acne and excess hair, as well infertility and long-term healthrelated concerns compromise quality of life and adversely impact on mood and psychological well-being [23,62].”
Self-citationDefects in beta-cell function in functional ovarian hyperandrogenism
O'Meara, N. M. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.5.1241 · Cited by 245 · cited 1×
“Specific abnormalities of insulin metabolism identified in PCOS include reductions in secretion [39,40], reduced hepatic extraction [40], impaired suppression of hepatic gluconeogenesis [41] and abnormalities in insulin receptor signalling [42].”
Polycystic Ovary Syndrome and Mental Health: A Review
Himelein, M. J., & Thatcher, S. S. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000243772.33357.84 · Cited by 239 · cited 1×
“Women with PCOS may therefore present with a variety of serious clinical sequalae including psychological problems (reduced quality of life, poor self-esteem, depression, anxiety) [23,24], reproductive manifestations (hirsutism, infertility and pregnancy complications) [25], and metabolic implications (insulin resista…”
The Effects of a Low-Carbohydrate, Ketogenic Diet on the Polycystic Ovary Syndrome: A Pilot Study
Mavropoulos, J. C., Yancy, W. S., Hepburn, J., & Westman, E. C. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-35 · Cited by 226 · cited 1×
“While reductions in weight, BMI, waist circumference, fasting insulin or testosterone were reported, these studies lacked a control group [ 77- 79 ].”
Coffey, S., Bano, G., & Mason, H. D. (2006) · Gynecological Endocrinology · doi:10.1080/09513590600604541 · Cited by 206 · cited 1×
“The challenges to feminine identity and body image due to obesity, acne and excess hair, as well infertility and long-term healthrelated concerns compromise quality of life and adversely impact on mood and psychological well-being [23,62].”
Basic Infertility Including Polycystic Ovary Syndrome
Brassard, M., AinMelk, Y., & Baillargeon, J.-P. (2008) · Medical Clinics of North America · doi:10.1016/j.mcna.2008.04.008 · Cited by 180 · cited 4×
“Obesity independently exacerbates infertility, reduces efficacy of infertility treatment and induces a greater risk of miscarriage [30].”
InfluentialMolecular progress in infertility: polycystic ovary syndrome
Legro, R. S., & Strauss, J. F. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03275-2 · Cited by 180 · cited 1×
“Genetic and environmental contributors to hormonal disturbances combine with other factors, including obesity, ovarian dysfunction and hypothalamic pituitary abnormalities to contribute to the aetiology of PCOS [10,11].”
Risk of T2DM and impaired fasting glucose among pcos subjects: Results of an 8-year follow-up
Boudreaux, M. Y., Talbott, E. O., Kip, K. E., Brooks, M. M., & Witchel, S. F. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0056-1 · Cited by 153 · cited 1×
“The risk of GDM occurs both independent of and is exacerbated by obesity [27, 47 ].”
Poehlman, E. T. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.7.2463 · Cited by 151 · cited 1×
“Incorporating simple moderate physical activity including structured exercise (at least 30 min/ day) and incidental exercise increases weight loss and improves clinical outcomes in PCOS, compared to diet alone [71].”
Meyer, C., McGrath, B. P., & Teede, H. J. (2007) · Diabetes Care · doi:10.2337/dc06-0618 · Cited by 148 · cited 3×
“Based on International Diabetes Federation recommendations [48,80], metformin has a role in prevention of diabetes where lifestyle therapy is inadequate.”
Self-citationInsulin Sensitivity in Women with Polycystic Ovary Syndrome
VrbÍková, J., Cibula, D., Dvor̆áková, K., Stanická, S., Šindelka, G., Hill, M., Fanta, M., Vondra, K., & Škrha, J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031378 · Cited by 147 · cited 3×
“Lean women with PCOS often but not always [13] have abnormalities of insulin secretion and action compared to weight-matched control subjects [41].”
Obesity, lipids, cardiovascular risk, and androgen excess
Wild, R. A. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80056-4 · Cited by 145 · cited 1×
“Dyslipidaemia is common in PCOS compared to weight matched controls [34-37], with higher triglycerides and lower high density lipoprotein cholesterol [35].”
Moran, L. J., Noakes, M., Clifton, P. M., Wittert, G. A., Williams, G., & Norman, R. J. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.1.77 · Cited by 141
Self-citationAnti-Müllerian Hormone Levels in Peripubertal Daughters of Women with Polycystic Ovary Syndrome
Crisosto, N., Codner, E., Maliqueo, M., Echiburú, B., Sánchez, F., Cassorla, F., & Sir-Petermann, T. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0267 · Cited by 138
The management of insulin resistance in polycystic ovary syndrome
Teede, H. J., Hutchison, S. K., & Zoungas, S. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.08.001 · Cited by 135 · cited 5×
“Given the increased insulin resistance and high risk of DM2, this includes PCOS especially if other risk factors including excess weight, family history of DM2, metabolic syndrome or prediabetes exist [22].”
InfluentialSelf-citationVascular Dysfunction and Metabolic Parameters in Polycystic Ovary Syndrome
Meyer, C., McGrath, B. P., Cameron, J., Kotsopoulos, D., & Teede, H. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1487 · Cited by 101 · cited 1×
“Also, increased early clinical and subclinical markers of atherosclerosis seen in PCOS (endothelial dysfunction, impaired pulse wave velocity, increased carotid intima media wall thickness, presence of carotid plaque and increased coronary artery calcification) [34,57] are further exacerbated by obesity [27,58,59].”
Self-citationBalen, A. (1995) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a136275 · Cited by 97
Sam, S., Legro, R. S., Essah, P. A., Apridonidze, T., & Dunaif, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602025103 · Cited by 96 · cited 1×
“Furthermore, emerging data shows increased risk of metabolic complications in firstdegree family members of women with PCOS [52-56].”
The effect of polycystic ovary syndrome on health-related quality of life
Coffey, S., & Mason, H. (2003) · Gynecological Endocrinology · doi:10.1080/09513590312331290268 · Cited by 94 · cited 1×
“Limited studies to date have reported that women who have PCOS are more prone to depression, anxiety, low self-esteem, negative body image, and psychosexual dysfunction [ 63 ,64].”
The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome
Wild, R. A., & Bartholomew, M. J. (1988) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(88)80099-1 · Cited by 92 · cited 2×
“The dyslipidaemia occurs independent of body mass index (BMI) [35,38] , however there is a synergistic deleterious effect of obesity and insulin resistance in PCOS analogous to that seen in DM2.”
Baillargeon, J., & Carpentier, A. C. (2007) · Diabetologia · doi:10.1007/s00125-007-0831-9 · Cited by 82 · cited 1×
“Furthermore, emerging data shows increased risk of metabolic complications in firstdegree family members of women with PCOS [52-56].”
Yılmaz, M., Bukan, N., Ersoy, R., Karakoç, A., Yetkin, İ., Ayvaz, G., Çakır, N., & Arslan, M. (2005) · Human Reproduction · doi:10.1093/humrep/dei070 · Cited by 82 · cited 1×
“Furthermore, emerging data shows increased risk of metabolic complications in firstdegree family members of women with PCOS [52-56].”
Hamilton‐Fairley, D., Kiddy, D., Anyaoku, V., Koistinen, R., Seppälä, M., & Franks, S. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb02378.x · Cited by 75 · cited 1×
“Evidence shows that lifestyle change with small achievable goals results in clinical benefits even when women remain in the overweight or obese range, [9,68,69].”
The Evaluation of Cognitive–Behavioral Group Therapy on Patient Depression and Self-Esteem
Chen, T.-H., Lu, R., Chang, A.-J., Chu, D.-M., & Chou, K. (2006) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2005.08.005 · Cited by 68 · cited 1×
“Education on short-term and long-term sequalae of PCOS from a reliable independent source is important in allaying anxiety and minimising the impact of illness in chronic disease (Table 2). As a prelude to treatment psychological features need to be acknowledged, discussed and counselling considered [ 65 ], to enable…”
Kasim-Karakas, S. E., Almario, R. U., & Cunningham, W. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.05.065 · Cited by 57 · cited 1×
“A number of small studies assessing specific dietary approaches in PCOS show similar results for diets moderately increased in dietary protein or carbohydrate [73-75] with one study reporting greater weight loss where a high protein supplement was added to a standard energy reduced diet [76].”
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub3 · Cited by 51
Hays, J. H., DiSabatino, A., Gorman, R. T., Vincent, S., & Stillabower, M. E. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.11.1331 · Cited by 50 · cited 1×
“While reductions in weight, BMI, waist circumference, fasting insulin or testosterone were reported, these studies lacked a control group [ 77- 79 ].”
A group program for obese, infertile women: weight loss and improved psychological health.
Galletly, C., Clark, A., Tomlinson, L., & Blaney, F. (1996) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.3109/01674829609025672 · Cited by 48 · cited 1×
“As little as 5% to 10% weight loss has significant clinical benefits improving psychological outcomes [66], reproductive features (menstrual cyclicity, ovulation and”
Herriot, A. M., Whitcroft, S., & Jeanes, Y. (2008) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2008.00890.x · Cited by 46 · cited 1×
“While reductions in weight, BMI, waist circumference, fasting insulin or testosterone were reported, these studies lacked a control group [ 77- 79 ].”
Wahrenberg, H., Ek, I., Reynisdottir, S., Carlström, K., Bergqvist, A., & Arner, P. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5794 · Cited by 45 · cited 1×
“Evidence shows that lifestyle change with small achievable goals results in clinical benefits even when women remain in the overweight or obese range, [9,68,69].”
Wahrenberg, H. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.2182 · Cited by 41
Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome
Doi, S. A. R., Al-Zaid, M., Towers, P. A., Scott, C. J., & Al-Shoumer, K. A. S. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03345319 · Cited by 26 · cited 1×
“Genetic and environmental contributors to hormonal disturbances combine with other factors, including obesity, ovarian dysfunction and hypothalamic pituitary abnormalities to contribute to the aetiology of PCOS [10,11].”
Ünlühızarcı, K., Özocak, M., Tanrıverdi, F., Atmaca, H., & Keleştimur, F. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.11.075 · Cited by 14 · cited 1×
“Furthermore, emerging data shows increased risk of metabolic complications in firstdegree family members of women with PCOS [52-56].”
Research works printed but not linked: 4
- Barr ELM Magliano DJ Zimmet PZ Polkinghorne KR Atkins RC Dunstan DW Murray SG Shaw JE AusDiab 2005: The Australian Diabetes, Obesity and Lifestyle Study 2006 Melbourne, Australia: International Diabetes Institute
- Dunstan D Zimmet P Welborne T Sicree RTA Atkins R Cameron A Shaw J Chadaban S Diabetes and associated disorders in Australia 2000 - the accelerating epidemic Australian Diabetes, Obesity and Lifestyle Report 2001 Melbourne, Australia: The International Diabetes Institute
- NHaMRC Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults 2003 Canberra, Australia: Australian Government Publishing Service
- Zawadzki J Dunaif A Dunaif A, Givens J, Haseltine F, Marrian G Diagnostic criteria for polycystic ovary syndrome: towards a rational approach Polycystic Ovary Syndrome Current Issues in Endocrinology and Metabolism 1992 Boston, MA: Blackwell Scientific 377 384
Cited by
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Self-citationTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., International PCOS Network, Andersen, M., et al. (2018) · Human Reproduction · doi:10.1093/humrep/dey256 · Cited by 1,593
Self-citationState-of-the-science of endocrine disrupting chemicals, 2012
Bergman, Å., Heindel, J., Jobling, S., Kidd, K., & Zoeller, R. T. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2012.03.020 · Cited by 1,388
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., Andersen, M., Azziz, R., et al. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.004 · Cited by 1,325
Self-citationEpidemiology, diagnosis, and management of polycystic ovary syndrome
Sirmans, S., & Pate, K. (2013) · Clinical Epidemiology · doi:10.2147/clep.s37559 · Cited by 1,302
“Because a dominant follicle does not develop, ovulation does not ensue.(14,15) In addition,”
Metadata
- Authors
- Teede, H., Deeks, A., & Moran, L.
- Affiliations
- Jean Hailes (AU)
- Corresponding author
- Moran, L
- Venue
- BMC Medicine
- Published
- 2010-06-30
- Volume
- 8
- Issue
- 1
- Pages
- 41-41
- ISSN
- 1741-7015 (ISSN-L)
- PMC
- PMC2909929
- OpenAlex
- W2058294720
- Cited by
- 1,565
- References
- 89
- Citations by year
- 2026: 83 · 2025: 139 · 2024: 156 · 2023: 145 · 2022: 155 · 2021: 171 · 2020: 122 · 2019: 102 · 2018: 87 · 2017: 78 · 2016: 57 · 2015: 53 · 2014: 75 · 2013: 63 · 2012: 42
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, insulin resistance, obesity, hyperandrogenism, hirsutism, infertility, cardiometabolic risk, type 2 diabetes, cardiovascular risk, anxiety, depression, quality of life, weight loss, lifestyle intervention, first-degree relatives, metabolic complications, psychological manifestations
- MeSH terms
- Anxiety, Cardiovascular Diseases, Depression, Diabetes Mellitus, Female, Hirsutism, Humans, Infertility, Ovary, Polycystic Ovary Syndrome, Quality of Life, Reproduction, Hyperandrogenism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.